NMOSD
Clinical trials for NMOSD explained in plain language.
Never miss a new study
Get alerted when new NMOSD trials appear
Sign up with your email to follow new studies for NMOSD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug for kids with rare nerve disease moves to final testing phase
Disease control Recruiting nowThis study tests a drug called satralizumab in children aged 2 to 11 with a rare disease called NMOSD, which causes inflammation in the nerves and spinal cord. The goal is to see how the drug works in the body, whether it is safe, and if it can prevent relapses. Only 8 children w…
Matched conditions: NMOSD
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 17, 2026 06:20 UTC
-
Engineered immune cells take aim at lupus and MS
Disease control Recruiting nowThis early-stage study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and calm overactive immune cells in autoimmune diseases. The trial includes 18 adults with conditions like lupus, systemic sclerosis, multiple sclerosis, and ot…
Matched conditions: NMOSD
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New registry to monitor Real-World impact of C5 inhibitors in rare neurological disease
Knowledge-focused Recruiting nowThis study is a long-term registry for adults with AQP4+ neuromyelitis optica spectrum disorder (NMOSD) who are already taking Alexion C5 inhibitor drugs (eculizumab or ravulizumab) to prevent relapses. Researchers will collect data on relapse rates, safety, and quality of life o…
Matched conditions: NMOSD
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC